SABS - SAB up 12% on Breakthrough Therapy tag for flu immunotherapy
2023-04-18 08:47:12 ET
- SAB Biotherapeutics ( NASDAQ: SABS ) is up ~12% in premarket trading Tuesday after the US FDA granted Breakthrough Therapy designation for its influenza immunotherapy candidate SAB-176.
- The drug is for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk individuals.
- SAB ( SABS ) shot up more than 85% on April 13 after the FDA awarded SAB-176 Fast Track status .
For further details see:
SAB up 12% on Breakthrough Therapy tag for flu immunotherapy